Wei Cui1, Yuna Liu2, Yanan Tan1, Xingyue Peng1, Longzhen Cui3, Zhiheng Cheng4, Yifeng Dai5, Lin Fu6,7,8, Tiansheng Zeng6,7, Yan Liu3. 1. Department of Clinical Laboratory, Beijing Haidian Hospital, Beijing Haidian Section of Peking University Third Hospital, Beijing, 100080, China. 2. Department of Clinical Laboratory Medicine, Beijing Hospital of Integrated Chinese & Western Medicine, Beijing, 100039, China. 3. Translational Medicine Center, Huaihe Hospital of Henan University, Kaifeng, 475000, China. 4. Department of Pathology & Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, 999025, Netherlands. 5. Immunoendocrinology, Division of Medical Biology, Department of Pathology & Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, 999025, Netherlands. 6. Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China. 7. Translational Medicine Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China. 8. Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, 475000, China.
Abstract
Aim: The objective of this work was to investigate the prognostic role of the HMGN family in acute myeloid leukemia (AML). Methods: A total of 155 AML patients with HMGN1-5 expression data from the Cancer Genome Atlas database were enrolled in this study. Results: In the chemotherapy-only group, patients with high HMGN2 expression had significantly longer event-free survival (EFS) and overall survival (OS) than those with low expression (all p < 0.05), whereas high HMGN5 expressers had shorter EFS and OS than the low expressers (all p < 0.05). Multivariate analysis identified that high HMGN2 expression was an independent favorable prognostic factor for patients who only received chemotherapy (all p < 0.05). HMGN family expression had no impact on EFS and OS in AML patients receiving allogeneic hematopoietic stem cell transplantation. Conclusion: High HMGN2/5 expression is a potential prognostic indicator for AML.
Aim: The objective of this work was to investigate the prognostic role of the HMGN family in acute myeloid leukemia (AML). Methods: A total of 155 AMLpatients with HMGN1-5 expression data from the Cancer Genome Atlas database were enrolled in this study. Results: In the chemotherapy-only group, patients with high HMGN2 expression had significantly longer event-free survival (EFS) and overall survival (OS) than those with low expression (all p < 0.05), whereas high HMGN5 expressers had shorter EFS and OS than the low expressers (all p < 0.05). Multivariate analysis identified that high HMGN2 expression was an independent favorable prognostic factor for patients who only received chemotherapy (all p < 0.05). HMGN family expression had no impact on EFS and OS in AMLpatients receiving allogeneic hematopoietic stem cell transplantation. Conclusion: High HMGN2/5 expression is a potential prognostic indicator for AML.